Tasimelteon
| Title | Journal |
|---|---|
| Tasimelteon: a selective and unique receptor binding profile. | Neuropharmacology 20150401 |
| Tasimelteon for the treatment of non-24-hour sleep-wake disorder. | Drugs of today (Barcelona, Spain : 1998) 20150101 |
| Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients. | CNS spectrums 20141201 |
| Cardiovascular effects of melatonin receptor agonists. | Expert opinion on investigational drugs 20121101 |
| Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. | Central nervous system agents in medicinal chemistry 20120901 |
| Circadian and wakefulness-sleep modulation of cognition in humans. | Frontiers in molecular neuroscience 20120101 |
| cGMP-phosphodiesterase inhibition enhances photic responses and synchronization of the biological circadian clock in rodents. | PloS one 20120101 |
| Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. | TheScientificWorldJournal 20120101 |
| Recent progress in the development of agonists and antagonists for melatonin receptors. | Current medicinal chemistry 20120101 |
| Melatonin receptor agonists: new options for insomnia and depression treatment. | CNS neuroscience & therapeutics 20111201 |
| Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection. | Therapeutic advances in neurological disorders 20110901 |
| Tasimelteon for insomnia. | Expert opinion on investigational drugs 20110701 |
| Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? | Progress in neuro-psychopharmacology & biological psychiatry 20110601 |
| Neurochemical and neuropharmacological aspects of circadian disruptions: an introduction to asynchronization. | Current neuropharmacology 20110601 |
| Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. | Neuroendocrinology 20110101 |
| Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. | Neuro endocrinology letters 20110101 |
| Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. | Advances in therapy 20101101 |
| [The newer sedative-hypnotics]. | Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20100901 |
| A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. | Current neuropharmacology 20100901 |
| Investigational melatonin receptor agonists. | Expert opinion on investigational drugs 20100601 |
| Melatonin agonists and insomnia. | Expert review of neurotherapeutics 20100201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. | Current opinion in investigational drugs (London, England : 2000) 20090701 |
| Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. | Neuroscience letters 20090626 |
| New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists. | Neuropsychiatric disease and treatment 20090101 |
| Melatonin and its agonists: an update. | The British journal of psychiatry : the journal of mental science 20081001 |
| Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application. | Journal of pharmaceutical and biomedical analysis 20050901 |
| Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. | Journal of pharmaceutical sciences 20030401 |